Breast cancer trial comparing two forms of paclitaxel
Treatments studied
Part of Cancer clinical trials.
This study checks if a generic version of paclitaxel protein-bound particles works the same as the brand-name drug in people with breast cancer. It's for patients whose cancer has spread or returned, and who might benefit from this medicine alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer that has spread or returned after previous treatment.
- You are between 18 and 75 years old.
- Your cancer doctor thinks paclitaxel alone is a good option for you.
- You are in generally good health, with adequate blood cell counts and liver/kidney function.
- You have not had major surgery in the last 4 weeks, and can avoid pregnancy for at least 6 months.
- You have no severe allergies to paclitaxel or human albumin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 trial compares two chemotherapy combinations to treat stage II–III triple-negative breast cancer. It looks for which regimen works better and is tolerated in people with measurable tumors and good overall health.
This study tests a new drug called SYHX2011 in people with advanced breast cancer. It looks at how well the drug works and if it is safe. The drug is a form of paclitaxel (a chemotherapy drug) bound to albumin, a protein.
This study tests whether a new version of paclitaxel (albumin-bound) works the same as the approved version in people with breast cancer. It's for patients whose cancer has spread or returned after other treatments, or those for whom this drug is recommended by treatment guidelines.
This study tests a combination of two medicines (albumin-bound paclitaxel and a granulocyte-based therapy) for women with breast cancer that has come back or spread. It may be an option if you have already tried standard treatment and are looking for another approach.
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
This trial tests a new form of the chemotherapy drug paclitaxel (called polymeric micellar paclitaxel) for people with pancreatic cancer that has spread to other parts of the body (metastatic). It's for those who haven't had any prior treatment for their metastatic cancer, and aims to see if this drug can help control the cancer.
Hear when a new Bioequivalence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.